Back to top
more

Bayer (BAYRY)

(Delayed Data from OTC)

$7.83 USD

7.83
949,726

+0.06 (0.77%)

Updated May 17, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 24% (189 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Pfizer (PFE) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Revenues from the COVID-19 vaccine and COVID pill, Paxlovid are likely to have driven Pfizer's (PFE) sales in the second quarter.

AbbVie (ABBV) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) second-quarter results are expected to reflect the impact of strong demand for immunology drugs, aesthetics and cosmetics products. Investors are likely to enquire on ABBV's plans to counter Humira LOE.

Merck (MRK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, and COVID-19 antiviral pill, molnupiravir when the company reports Q2 earnings.

GSK Gears Up to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company reports.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance

by Zacks Equity Research

J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.

Sejuti Banerjea headshot

Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood

by Sejuti Banerjea

JNJ Management expects relatively consistent growth for the rest of the year.

John Blank headshot

Q2 Earnings Create Waves: Global Week Ahead

by John Blank

Management updates can create major waves, as they produce a cascade of earnings estimates revisions, across a number of S&P 500 sectors and industries.

Sanofi (SNY) Dupixent Esophagitis Kids Study Meets Goal

by Zacks Equity Research

Sanofi's (SNY) Dupixent shows the potential to improve signs of eosinophilic esophagitis in a phase III pivotal study in children 1 to 11 years of age.

Merck (MRK) Buys Rights to Mid-Stage Prostate Cancer Candidate

by Zacks Equity Research

Merck (MRK) is set to make an upfront payment of $290 million to Orion for co-development and co-commercialization rights to ODM-208.

Kinjel Shah headshot

3 Drugmaker Stocks Worth Buying to Boost Your Portfolio Health

by Kinjel Shah

Merck (MRK), Bayer (BAYRY) and Jazz Pharmaceuticals (JAZZ) are three large drugmakers that are good stocks to buy.

BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

by Zacks Equity Research

BAYRY vs. RHHBY: Which Stock Is the Better Value Option?

Regeneron (REGN) Eylea sBLA for Extended Regimen Accepted

by Zacks Equity Research

FDA accepts Regeneron's (REGN) application seeking label expansion for Eylea for an extended period in patients with diabetic retinopathy.

The Zacks Analyst Blog Highlights UnitedHealth, Chevron, AstraZeneca, SAP and Bayer ktiengesellschaftt

by Zacks Equity Research

UnitedHealth, Chevron, AstraZeneca, SAP and Bayer ktiengesellschaftt are part of Zacks top Analyst Blog.

Mark Vickery headshot

Top Analyst Reports for UnitedHealth, Chevron & AstraZeneca

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth Group Incorporated (UNH), Chevron Corporation (CVX), and AstraZeneca PLC (AZN).

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Regeneron's (REGN) Evkeeza Positive in Late-Stage Study

by Zacks Equity Research

Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.

Neena Mishra headshot

3 ETFs to Fight Surging Food Inflation

by Neena Mishra

Russia-Ukraine war has sent food prices soaring

Kinjel Shah headshot

Pharma Stock Roundup: PFE's Biohaven Buyout Offer, BAYRY's Q1 Earnings Update

by Kinjel Shah

Pfizer (PFE) is set to buy migraine drugmaker, Biohaven Pharmaceuticals for $11.6 billion. Bayer (BAYRY) beats Q1 earnings and sales expectations.

    Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus

    by Zacks Equity Research

    Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

    Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1

    by Zacks Equity Research

    Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.

    Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected

    by Zacks Equity Research

    Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.

    Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M

    by Zacks Equity Research

    Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.

    Amgen's (AMGN) Stelara Biosimilar Meets Psoriasis Study Goal

    by Zacks Equity Research

    Initial data from a late-stage study comparing Amgen's (AMGN) Stelara biosimilar candidate with the original Stelara drug showed no clinically meaningful differences in treating plaque psoriasis.